The article titled “Paradoxical Psoriasis: The Flip Side of TNF-α Inhibitors”, submitted to Clinical Pharmacy Connect, has been formally withdrawn.

Following concerns raised by several co-authors regarding the submission, it was identified that the manuscript had been submitted by the corresponding without the knowledge and written approval of all listed authors. Additionally, the revised version was submitted without co-authors’ approval and consent. These issues reflect practices that do not align with the journal’s ethical requirements for authorship and co-authors’ agreement.

In line with ICMJE authorship standards (all authors must approve the submitted and revised/final versions) and to protect the integrity of the scholarly record (as per COPE guidance), the journal has withdrawn the manuscript and it will not proceed to publication. This is also to inform that the manuscript was still in under editorial handling / pre-publication stage and was not published. The manuscript files are no longer publicly accessible. This notice is retained to maintain transparency in the scholarly record. The Publisher/Editorial Office apologizes for any inconvenience caused

We acknowledge the co-authors’ cooperation and thank all parties for their understanding.